Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

FIVE at FIVE AU: ASX higher as jobless rate lifts; Altium soars on takeover offer

Published 15/02/2024, 04:05 pm
Updated 15/02/2024, 04:30 pm
© Reuters FIVE at FIVE AU: ASX higher as jobless rate lifts; Altium soars on takeover offer

The ASX finished higher today with the benchmark ASX 200 index gaining 0.77% as the ABS reported a lift in the jobless rate in January.

The Tech sector led the gains, up a massive 6.81%. A $9.1 billion takeover bid for Altium at a premium price of close to 39% lifted the sector. Altium’s shares gained 28.76% to $66, while software peers Wisetech (+4.77%) and Xero (+5.77%) gained.

Real Estate was also strong, up 3.37%, and Consumer Discretionary stocks gained 2.77%. Energy, meanwhile, was in the red, losing 2.10%.

Jobless rate rises

The ABS reports Australia’s unemployment rate has risen above 4% for the first time since January 2022, affected by higher interest rates and workers taking a break over the summer holidays.

The number of unemployed people rose by 22,000 last month, lifting the jobless rate to 4.1%, up from 3.9% in December.

Treasurer Jim Chalmers said the rise in unemployment was an “inevitable consequence” of higher interest rates, persistent inflation and global economic uncertainty, after the creation of a record 650,000 jobs under Labor.

The rise comes from a strong position, with Chalmers highlighting that last year was the first time since records began 46 years ago that unemployment had been below 4% every month.

Five at five

Suvo Strategic Minerals targets $3.5 million for Pittong operations and geopolymer concrete research

Suvo Strategic Minerals Ltd (ASX:SUV) has $2.5 million to play with following a placement to sophisticated investors and is targeting an additional $1 million in a share purchase plan (SPP).

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read more

Accelerate Resources confirms lithium mineralisation continuity at Prinsep ahead of drilling

Accelerate Resources Ltd (ASX:AX8) has confirmed extended lithium mineralisation at Prinsep Lithium Project in Western Australia's West Pilbara region, setting the stage for imminent drilling activities.

Read more

Kin Mining cashed up and seeking complementary assets; makes offer for PNX Metals

With approximately $75 million in cash and liquid assets, a cashed-up Kin Mining NL (ASX:KIN) is seeking to invest in projects considered prospective for gold and other metals and, as such, has made a play for PNX Metals Ltd (ASX:PNX).

Read more

Kingston Resources confirms Mineral Hill discovery with results up to 6.37% copper equivalent

Kingston Resources Ltd (ASX:KSN) has confirmed the presence of a new copper discovery in the Southern Ore Zone (SOZ) less than 200 metres from existing underground development at the Mineral Hill Project in central New South Wales.

Read more

Ora Banda Mining on track for first stoping ore in March and commercial gold production next quarter

Ora Banda Mining Ltd (ASX:OBM) is on track to deliver the first stoping ore next month from the Riverina Underground operations in Western Australia with all capital projects complete and steady-state production expected in the June quarter.

Read more

On your six

Mixed signs for copper but demand from renewable energy and EVs strengthening

A look at some of the ASX-listed copper plays that made progress during the December quarter of 2023.

Read more

One to watch

Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong sits down with Jonathan Jackson in the Proactive studio to delve into the company’s latest milestone - commencement of dosing for the first patient in the intravenous monotherapy arm of a Phase 1 clinical trial of the CD19 oncolytic virotherapy drug candidate, onCARlytics (also known as on-CAR-19, CF33-CD19 HOV4).

Watch mor

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.